BiomiX-Driven Multi-Omics Integration of PRECISESADS Data Reveals Lysophosphatidic Acid and Metabolic Pathway Signatures in B Cells and Immune Macroenvironment in Sjogren's Disease

Iperi, C.; Fernandez-Ochoa, A.; Marec, N.; Pochard, P.; Pers, J.-O.; Barturen, G.; Alarcon-Riquelme, M.; PRECISESADS Flow Cytometry Study Group,; PRECISESADS Clinical Consortium,; Quirantes-Pine, R.; Borras-Linares, I.; Segura-Carretero, A.; Devauchelle-pensec, V.; Cornec, D.; Jamin, C.; Bordron, A.

doi:10.64898/2025.11.30.690253

bioRxiv · 10.64898/2025.11.30.690253

BiomiX-Driven Multi-Omics Integration of PRECISESADS Data Reveals Lysophosphatidic Acid and Metabolic Pathway Signatures in B Cells and Immune Macroenvironment in Sjogren's Disease

Iperi, C.·Fernandez-Ochoa, A.·Marec, N.·Pochard, P.·Pers, J.-O.·Barturen, G.·Alarcon-Riquelme, M.·PRECISESADS Flow Cytometry Study Group,·PRECISESADS Clinical Consortium,·Quirantes-Pine, R.·Borras-Linares, I.·Segura-Carretero, A.·Devauchelle-pensec, V.·Cornec, D.·Jamin, C.·Bordron, A.

View original source ↗Export metadata ↓

Abstract

ObjectiveSjogrens disease (SjD) is a systemic autoimmune disorder characterized by lymphocytic infiltration of exocrine glands, resulting in xerostomia, keratoconjunctivitis sicca, fatigue, arthralgia, and systemic organ involvement. This study aimed to characterize the metabolic and immune dysregulation of SjD using a multi-omics approach, focusing on the metabolic environment and B-cell transcriptomic responses. MethodsTranscriptomic, methylomic, and metabolomic datasets from whole blood, plasma, and urine of 293 SjD patients and 508 controls were analyzed from the PRECISESADS study. B-cell transcriptomes were included to link systemic metabolic alterations to cell-intrinsic immune programs. Multi-omics factor analysis (MOFA) was used to integrate data and identify discriminant molecular drivers. ResultsMulti-omics integration revealed metabolic rewiring involving the urea cycle, glutamine/arginine metabolism, and NAD depletion linked to interferon signaling. Among the strongest contributors, plasma lysophosphatidic acids (LPA) emerged as key discriminants associated with interferon-driven activation. B-cell transcriptomes showed upregulation of LPA-related genes (CERS6, INPP1, TRIP6), and its receptor LPAR6. Importantly, in this study LPAR6 protein expression was confirmed in B cells for the first time. Secondary findings included alterations in sphingosine-1-phosphate (S1P) metabolism, suggesting a broader lysophospholipid signaling axis. ConclusionsThis study identifies the LPA-LPAR6 signaling axis as a potential metabolic driver of B-cell activation and interferon-associated inflammation in SjD, highlighting a previously unrecognized immunometabolic pathway. These findings highlight LPA-LPAR6 as a candidate target for therapeutic modulation in SjD, while also implicating S1P signaling as a complementary regulatory mechanism.

Explore related subjects

immunology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Iperi, C., Fernandez-Ochoa, A., Marec, N., Pochard, P., Pers, J.-O., Barturen, G., Alarcon-Riquelme, M., PRECISESADS Flow Cytometry Study Group,, PRECISESADS Clinical Consortium,, Quirantes-Pine, R., Borras-Linares, I., Segura-Carretero, A., Devauchelle-pensec, V., Cornec, D., Jamin, C., Bordron, A.. 2025-12-02. BiomiX-Driven Multi-Omics Integration of PRECISESADS Data Reveals Lysophosphatidic Acid and Metabolic Pathway Signatures in B Cells and Immune Macroenvironment in Sjogren's Disease. https://doi.org/10.64898/2025.11.30.690253

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Common viral infections seed regionally distinct resident memory T cells in the human CNS

T cells persist in the central nervous system (CNS) and can drive both protection and neurological disease. How these cells are organized in humans and what they recognize is largely unknown. Here, we profiled CD8 T cells across anatomically distinct CNS regions, obtained through on-site autopsies and temporal lobe resection surgeries, using single-cell RNA sequencing, paired T cell receptor sequencing, and DNA-barcoded tetramers. Resident memory T cells (TRM) specific for Epstein-Barr virus, cytomegalovirus, influenza A, and SARS-CoV-2 were identified across CNS compartments. Anatomical location was the strongest correlate of TRM cell state, with leptomeningeal cells adopting a cytokine-poised TRM program, whereas brain TRM cells were transcriptionally restrained. Cells of the same clonotype spanned tissues yet adopted local transcriptional states. Viral specificity added another layer of TRM heterogeneity with GZMK/GZMA-expressing EBV-specific populations and interferon-stimulated gene signatures in SARS-CoV-2 and Influenza A-specific cells. The human CNS thus harbors regionally distinct CD8+ TRM shaped by common viral exposures.

immunology↗

bioRxiv2026

A regulatory T cell signature provides a shared molecular basis for the therapeutic window of opportunity in rheumatic disease

Rheumatic diseases, including rheumatoid arthritis (RA), spondyloarthritis (SpA) and osteoarthritis (OA), show distinct phenotypes yet respond to overlapping therapies, implicating shared immune mechanisms. In the Transimmunom cohort, we profiled peripheral blood from 240 individuals (47 healthy, 44 OA, 91 RA, 58 SpA) across deep immunophenotyping, immunoproteomics and Treg-Teff transcriptomics. Single-layer analyses revealed broader Treg than Teff remodeling, along with a shared pattern of reduced activated Tregs and expanded Helios+ Tregs across all diseases, alongside a decrease in functional Treg subpopulations, including CTLA4+ and CD45RA- Tregs. In RA specifically, LAG3+ Tregs were also expanded. Combining omics layers outperformed single-layer approaches for disease classification. Among individual layers, Treg transcriptomes were most discriminative, and integration uncovered disease-specific programs. Unsupervised clustering identified a cross-disease cluster independent of activity, treatment and age, mapping to early disease (<= years) and dominated by a Treg dysfunction-associated program. These results provide a biological rationale for the therapeutic "window of opportunity" concept and duration-stratified Treg-directed trials.

immunology↗

bioRxiv2026

Inhibitory Fc Receptor sets a time limit on macrophage response to IgG

Antibodies engage both activating Fc Receptors and the inhibitory receptor Fc{gamma}RIIB. Why macrophages need a dedicated inhibitory receptor rather than simply tuning activating receptor signaling is unclear. Using DNA-based chimeric receptors and in silico modeling, we independently controlled activating and inhibitory Fc Receptors. We found that Fc{gamma}RIIB imposed a time limit on macrophage phagocytosis and ERK signaling. The time limit is due to activating Fc Receptors converting PI(4,5)P2 to PI(3,4,5)P3, which is subsequently converted to PI(3,4)P2 by Fc{gamma}RIIB. This leads to a pulse of active signaling, which is sufficient for phagocytosis of small bacteria-sized targets but not phagocytosis of large targets and TNF secretion. Unlike engaging Fc{gamma}RIIB, reducing activating Fc Receptor signaling decreased initiation of phagocytosis, the speed of PI(3,4,5)P3 generation, and the amplitude of ERK signaling. Our results demonstrate that Fc{gamma}RIIB controls the duration of IgG signaling, while the activating Fc Receptors control sensitivity.

immunology↗